Immuntherapie beim Ösophagus Karzinom
| Autor: | Josef Friedl, Stefan Riss, Anton Stift |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
medicine.medical_specialty Lymphokine-activated killer cell biology Tumor-infiltrating lymphocytes business.industry medicine.medical_treatment Immunotherapy Esophageal cancer medicine.disease Clinical trial Immune system Internal medicine Immunology medicine biology.protein Surgery Antibody Antigen-presenting cell business |
| Zdroj: | European Surgery. 39:158-166 |
| ISSN: | 1682-4016 1682-8631 |
| DOI: | 10.1007/s10353-007-0334-4 |
| Popis: | BACKGROUND: The advances in surgical techniques and the development of new therapeutic agents have improved the prognosis of esophageal cancer in the past decades. However, the 5 year overall survival still remains poor. The bleak prognosis has led to the search for new therapeutic options such as immunotherapy. METHODS: Review of the literature and presentation of institutional experience in immunotherapy. RESULTS: In the past two decades, adoptive immunotherapy based on tumor infiltrating lymphocytes (TILs) or lymphokine activated killer cells (LAK) has been used in clinical trials. The increasing knowledge about the central role of professional antigen presenting cells (Dendritic cells; DCs) in the regulation of the immune system and the mechanism controlling the function of the involved effector cells have provided new possibilities for cancer treatment. CONCLUSIONS: Immunotherapy in combination with established therapeutical modalities is a possible approach for the treatment of esophageal cancer that may in the future further improve the prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|